Monopar Therapeutics (MNPR) Shares Outstanding: 2016-2020
Historic Shares Outstanding for Monopar Therapeutics (MNPR) over the last 3 years, with Sep 2020 value amounting to $11.5 million.
- Monopar Therapeutics' Shares Outstanding rose 23.26% to $11.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was $11.5 million, marking a year-over-year increase of 23.26%. This contributed to the annual value of $10.6 million for FY2019, which is 13.95% up from last year.
- As of Q3 2020, Monopar Therapeutics' Shares Outstanding stood at $11.5 million, which was up 6.67% from $10.7 million recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Shares Outstanding ranged from a high of $11.5 million in Q3 2020 and a low of $115,894 during Q4 2016.
- Its 3-year average for Shares Outstanding is $9.9 million, with a median of $9.3 million in 2019.
- Data for Monopar Therapeutics' Shares Outstanding shows a peak YoY spiked of 7,917.17% (in 2017) over the last 5 years.
- Quarterly analysis of 5 years shows Monopar Therapeutics' Shares Outstanding stood at $115,894 in 2016, then skyrocketed by 7,917.17% to $9.3 million in 2017, then remained steady at $9.3 million in 2018, then climbed by 13.95% to $10.6 million in 2019, then rose by 23.26% to $11.5 million in 2020.
- Its Shares Outstanding was $11.5 million in Q3 2020, compared to $10.7 million in Q2 2020 and $10.6 million in Q1 2020.